Search

Your search keyword '"Schmid‐Grendelmeier, Peter"' showing total 897 results
Start Over Author "Schmid‐Grendelmeier, Peter"
897 results on '"Schmid‐Grendelmeier, Peter"'

1. Sensitizations to pollen differ between Central European and Sub-Saharan African atopic dermatitis patients

Author

Fehr, Danielle, Rentschler, Muriel, Sendrasoa, Fandresena, Li, Nick, White, Anna, Distler, Meike, Lang, Claudia, Masenga, Gloria, Mosha, Nelson, Semango, George, Clemens, Clara, Rasamoelina, Tahinamandranto, Soankasina, Abel Hermann, Rapelanoro Rabenja, Fahafahantsoa, Mavura, Daudi, Masenga, John Elisante, Schmid-Grendelmeier, Peter, and Brüggen, Marie-Charlotte

Published
2024
Full Text
View/download PDF

3. Cutaneous and systemic hyperinflammation drives maculopapular drug exanthema in severely ill COVID‐19 patients

Author

Mitamura, Yasutaka, Schulz, Daniel, Oro, Saskia, Li, Nick, Kolm, Isabel, Lang, Claudia, Ziadlou, Reihane, Tan, Ge, Bodenmiller, Bernd, Steiger, Peter, Marzano, Angelo, Prost, Nicolas, Caudin, Olivier, Levesque, Mitchell, Stoffel, Corinne, Schmid‐Grendelmeier, Peter, Maverakis, Emanual, Akdis, Cezmi A, and Brüggen, Marie‐Charlotte

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Biotechnology, Inflammatory and immune system, Good Health and Well Being, CD8-Positive T-Lymphocytes, COVID-19, Exanthema, Humans, Pharmaceutical Preparations, Proteomics, SARS-CoV-2, coronavirus, drug-induced maculopapular exanthema, Immunology, Allergy
Abstract

BackgroundCoronavirus disease-2019 (COVID-19) has been associated with cutaneous findings, some being the result of drug hypersensitivity reactions such as maculopapular drug rashes (MDR). The aim of this study was to investigate whether COVID-19 may impact the development of the MDR.MethodsBlood and skin samples from COVID-19 patients (based on a positive nasopharyngeal PCR) suffering from MDR (COVID-MDR), healthy controls, non-COVID-19-related patients with drug rash with eosinophilia and systemic symptoms (DRESS), and MDR were analyzed. We utilized imaging mass cytometry (IMC) to characterize the cellular infiltrate in skin biopsies. Furthermore, RNA sequencing transcriptome of skin biopsy samples and high-throughput multiplexed proteomic profiling of serum were performed.ResultsIMC revealed by clustering analyses a more prominent, phenotypically shifted cytotoxic CD8+ T cell population and highly activated monocyte/macrophage (Mo/Mac) clusters in COVID-MDR. The RNA sequencing transcriptome demonstrated a more robust cytotoxic response in COVID-MDR skin. However, severe acute respiratory syndrome coronavirus 2 was not detected in skin biopsies at the time point of MDR diagnosis. Serum proteomic profiling of COVID-MDR patients revealed upregulation of various inflammatory mediators (IL-4, IL-5, IL-6, TNF, and IFN-γ), eosinophil and Mo/Mac -attracting chemokines (MCP-2, MCP-3, MCP-4 and CCL11). Proteomics analyses demonstrated a massive systemic cytokine storm in COVID-MDR compared with the relatively milder cytokine storm observed in DRESS, while MDR did not exhibit such features.ConclusionA systemic cytokine storm may promote activation of Mo/Mac and cytotoxic CD8+ T cells in severe COVID-19 patients, which in turn may impact the development of MDR.

Published
2022

5. Severe Asthma Standard-of-Care Background Medication Reduction With Benralizumab: ANDHI in Practice Substudy

Author

Pohl, Wolfgang, Doberer, Daniel, Martinot, Jean Benoit, Deschampheleire, Maud, Himpe, Ulrike, Chapman, Kenneth, Cheema, Amarjit, Dorscheid, Delbert, Ramsey, Clare, Rolf, Jeffrey, Walker, Brandie, Olivenstein, Ronald, Poirier, Claude, Larivee, Pierre, Bjerrum, Anne Sofie, Titlestad, Ingrid, Hilberg, Ole, Kilpeläinen, Maritta, Bonniaud, Philippe, Taillé, Camille, Tiotiu, Iuliana-Angelica, Girodet, Pierre-Olivier, Blanc, François-Xavier, Pradelli, Johana, Didier, Alain, Nocent Ejnaini, Cecilia, Deslee, Gaetan, Pison, Christophe, Douadi, Youcef, Mahay, Guillaume, Devouassoux, Gilles, Melloni, Boris, Roux, Pauline-Marie, Bourdin, Arnaud, Fry, Stephanie, Schaum, Thomas, Schulz, Christian, Skowasch, Dirk, Taube, Christian, Welte, Tobias, Gleiber, Wolfgang, Brehler, Randolf, Schreiber, Jens, Schuette, Wolfgang, Kronsbein, Juliane, Bonnet, Reiner, Beck, Ekkehard, Lacedonia, Donato, Senna, Gianenrico, Caruso, Cristiano, Crimi, Nunzio, Blasi, Francesco, Santus, Pierachille, Canonica, Giorgio Walter, Guarnieri, Gabriella, Pelaia, Girolamo, Milanese, Manlio, Micheletto, Claudio, Corsico, Angelo Guido, Scichilone, Nicola, Spadaro, Giuseppe, Langeveld, Bas, Holters, Jurgen, Willem van den Berg, Jan, Smit, Arthur, Conemans, Lennart, van Veen, Helena, Staaks, Gerald, Lehmann, Sverre, Echave-Sustaeta, Jose Maria, Ribas, Christian Domingo, de Luiz Martinez, Gustavo, Gonzalez Perez, Ruperto, Garcia Rivero, Juan Luis, Gall, Xavier Muñoz, Soto Campos, Jose Gregorio, Mozo, Paloma Campo, Pan, Carmen Vidal, Fernandez, Ana Gomez-Bastero, Tellez, Sergio Campos, Rivera, Carlos Martinez, Bobolea, Irina Diana, Guerrero, Raquel Morillo, Garcia, Ismael Ali, Rodriguez Hermosa, Juan Luis, Stenfors, Nikolai, Tunsäter, Alf, Curiac, Dan, von Garnier, Christophe, Leuppi, Joerg, Schmid-Grendelmeier, Peter, Nasser, Shuaib, Chaudhuri, Rekha, Nordstrom, Monica, Saralaya, Dinesh, Pfeffer, Paul, Mansur, Adel, Short, Philip, Wenzel, Sally, Cherry, William Brett, Zafra, Heidi, Gonzalez, Erika, Soong, Weily, Davis, Benjamin, Kao, Neil, Hussain, Iftikhar, Maselli Caceres, Diego Jose, Harris, James, Calhoun, William, Rodicio, Ileana, Kaufman, David, Moss, Mark, Sztejman, Eric, DeLeon, Samuel, Sumino, Kaharu, Kashyap, Ravindra, Leflein, Jeffrey, Hajal, Rizan, Fakih, Faisal, Hill, David, Lin, Robert, Jarratt, Mikell, Subramaniam, Vijay, Sussman, Robert, Mumneh, Nayla, Reibman, Joan, Darveaux, Jared, Tan, Ricardo, Tanus, Tonny, Sikand, Vinay, Marshall, Gailen, Mehta, Hemalini, Cole, Jeremy, Goodman, Brad, Goss, Deborah, Bardelas, Jose, Milstone, Aaron, Mehta, Vinay, Clore, Lee, Millard, Mark, Palumbo, Michael, Puppala, Dileep, Leong, Mila, Prenner, Bruce, Robinette, Emory, Heidarian Raissy, Hengameh, Fost, David, Pleskow, Warren, Marcus, Michael, Ilowite, Jonathan, Moore, Wendy, Steven, Gary, De la Cruz, Luis, Chupp, Geoffrey, Berger, William, Randolph, Christopher, Holguin, Fernando, Kureishy, Shahrukh, Campbell, Edward, Peche, Rudi, Pini, Laura, Papi, Alberto, Beghé, Bianca, Peveri, Silvia, Henriquez Santa, Aythamy, Ramos Gonzalez, Jacinto, Vinge, Ines, St. John, Roy, Louis, Renaud, Harrison, Tim W., Chanez, Pascal, Menzella, Francesco, Philteos, George, Cosio, Borja G., Lugogo, Njira L., de Luiz, Gustavo, Burden, Annie, Adlington, Timothy, Keeling, Nanna, Kwiatek, Justin, and Garcia Gil, Esther

Published
2023
Full Text
View/download PDF

8. Comprehensive Approach: Current Status on Patient Education in Atopic Dermatitis and Other Allergic Diseases

Author

Traidl, Stephan, Lang, Claudia, Schmid-Grendelmeier, Peter, Werfel, Thomas, Heratizadeh, Annice, Barrett, James E., Editor-in-Chief, Flockerzi, Veit, Editorial Board Member, Frohman, Michael A., Editorial Board Member, Geppetti, Pierangelo, Editorial Board Member, Hofmann, Franz B., Editorial Board Member, Kuner, Rohini, Editorial Board Member, Michel, Martin C., Editorial Board Member, Page, Clive P., Editorial Board Member, Wang, KeWei, Editorial Board Member, Rosenthal, Walter, Editorial Board Member, Traidl-Hoffmann, Claudia, editor, Zuberbier, Torsten, editor, and Werfel, Thomas, editor

Published
2022
Full Text
View/download PDF

10. Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses

Author

Birkmann, Katharina, primary, Jebbawi, Fadi, additional, Waldern, Nina, additional, Hug, Sophie, additional, Inversini, Victoria, additional, Keller, Giulia, additional, Holm, Anja, additional, Grest, Paula, additional, Canonica, Fabia, additional, Schmid-Grendelmeier, Peter, additional, and Fettelschoss-Gabriel, Antonia, additional

Published
2024
Full Text
View/download PDF

11. Navigating the Evolving Landscape of Atopic Dermatitis: Challenges and Future Opportunities: the 4 th Davos Declaration

Author

Traidl-Hoffmann, Claudia, primary, Afghani, Jamie, additional, Akdis, Cezmi, additional, Akdis, Mubeccel, additional, Handan, Aydin, additional, Baerenfaller, Katja, additional, Behrendt, Heidrun, additional, Bieber, Thomas, additional, Bigliardi, Paul L., additional, Bigliardi-Qi, Mei, additional, Bonefeld, Charlotte, additional, Bösch, Stefanie, additional, Brüggen, Marie-Charlotte, additional, Diemert, Sebastian, additional, Duchna, Hans-Werner, additional, Fähndrich, Martina, additional, Fehr, Danielle, additional, Fellmann, Marc, additional, Frei, Remo, additional, Garvey, Lene, additional, Gharbo, Raschid, additional, Gökkaya, Mehmet, additional, Grando, Karin, additional, Guillet, Carole, additional, Güler, Erman, additional, Gutermuth, Jan, additional, Herrmann, Nadine, additional, Hijnen, DirkJan, additional, Hülpüsch, Claudia, additional, Irvine, Alan, additional, Jensen-Jarolim, Erika, additional, Kong, Heidi H, additional, Koren, Hillel, additional, Lang, Claudia, additional, Lauener, Roger, additional, Maintz, Laura, additional, Mantel, Pierre-Yves, additional, maverakis, Emanual, additional, Moehrenschlager, Matthias, additional, Müller, Svenja, additional, Nadeau, Kari, additional, Neumann, Avidan U., additional, O'Mahony, Liam, additional, Rabenja, Fahafahantsoa Rapelanoro, additional, Renz, Harald, additional, Rhyner, Claudio, additional, Rietschel, Ernst, additional, Ring, Johannes, additional, Roduit, Caroline, additional, Sasaki, Mari, additional, Schenk, Mirjam, additional, Schroder, Jens, additional, Simon, Dagmar, additional, Simon, Hans-Uwe, additional, Sokolowska, Milena, additional, stander, sonja, additional, Steinhoff, Martin, additional, Piccirillo, Doris Straub, additional, Taïeb, Alain, additional, Takaoka, Roberto, additional, Tapparo, Martin, additional, Teixeira, Henrique, additional, Thyssen, Jacob, additional, Traidl, Stephan, additional, Uhlmann, Miriam, additional, Veen, Willem van de, additional, Hage, Marianne van, additional, Virchow, Christian, additional, Wollenberg, Andreas, additional, mitamura, yasutaka, additional, Zink, Alexander, additional, and Schmid-Grendelmeier, Peter, additional

Published
2024
Full Text
View/download PDF

14. “Chronic urticaria and obstructive sleep apnea: Is there a significant association?”

Author

Cherrez-Ojeda, Ivan, Maurer, Marcus, Felix, Miguel, Bernstein, Jonathan A., Ramon, German D., Jardim Criado, Roberta Fachini, Mata, Valeria L., Cherrez, Annia, Morfin-Maciel, Blanca María, Larco, José Ignacio, Tinoco, Iván O., Chorzepa, Gonzalo Federico, Gómez, René Maximiliano, Raad, Rodolfo Jaller, Thomsen, Simon Francis, Schmid-Grendelmeier, Peter, Guillet, Carole, Cherrez, Sofia, and Vanegas, Emanuel

Published
2021
Full Text
View/download PDF

16. Navigating the evolving landscape of atopic dermatitis:Challenges and future opportunities: The 4th Davos declaration

Author

Traidl-Hoffmann, Claudia, Afghani, Jamie, Akdis, Cezmi, Akdis, Mubecel, Aydin, Handan, Barenfaller, Katja, Behrendt, Heidrun, Bieber, Thomas, Bigliardi, Paul, Bigliardi-Qi, Mei, Bonefeld, Charlotte Menne, Bosch, Stefanie, Bruggen, Marie Charlotte, Diemert, Sebastian, Duchna, Hans-Werner, Fahndrich, Martina, Fehr, Danielle, Fellmann, Marc, Frei, Remo, Garvey, Lena H., Gharbo, Raschid, Goekkaya, Mehmet, Grando, Karin, Guillet, Carole, Guler, Erman, Gutermuth, Jan, Herrmann, Nadine, Hijnen, Dirk Jan, Huelpuesch, Claudia, Irvine, Alan D., Jensen-Jarolim, Erika, Kong, Heidi H., Koren, Hillel, Lang, Claudia C. V., Lauener, Roger, Maintz, Laura, Mantel, Pierre-Yves, Maverakis, Emanuel, Mohrenschlager, Matthias, Mueller, Svenja, Nadeau, Kari, Neumann, Avidan U., O'Mahony, Liam, Rabenja, Fahafahantsoa Rapelanoro, Renz, Harald, Rhyner, Claudio, Rietschel, Ernst, Ring, Johannes, Roduit, Caroline, Sasaki, Mari, Schenk, Mirjam, Schroeder, Jens, Simon, Dagmar, Simon, Hans-Uwe, Sokolowska, Milena, Staender, Sonja, Steinhoff, Martin, Piccirillo, Doris Straub, Taieb, Alain, Takaoka, Roberto, Tapparo, Martin, Teixeira, Henrique, Thyssen, Jacob Pontoppidan, Traidl, Stephan, Uhlmann, Miriam, van de Veen, Willem, van Hage, Marianne, Virchow, Christian, Wollenberg, Andreas, Yasutaka, Mitamura, Zink, Alexander, Schmid-Grendelmeier, Peter, Traidl-Hoffmann, Claudia, Afghani, Jamie, Akdis, Cezmi, Akdis, Mubecel, Aydin, Handan, Barenfaller, Katja, Behrendt, Heidrun, Bieber, Thomas, Bigliardi, Paul, Bigliardi-Qi, Mei, Bonefeld, Charlotte Menne, Bosch, Stefanie, Bruggen, Marie Charlotte, Diemert, Sebastian, Duchna, Hans-Werner, Fahndrich, Martina, Fehr, Danielle, Fellmann, Marc, Frei, Remo, Garvey, Lena H., Gharbo, Raschid, Goekkaya, Mehmet, Grando, Karin, Guillet, Carole, Guler, Erman, Gutermuth, Jan, Herrmann, Nadine, Hijnen, Dirk Jan, Huelpuesch, Claudia, Irvine, Alan D., Jensen-Jarolim, Erika, Kong, Heidi H., Koren, Hillel, Lang, Claudia C. V., Lauener, Roger, Maintz, Laura, Mantel, Pierre-Yves, Maverakis, Emanuel, Mohrenschlager, Matthias, Mueller, Svenja, Nadeau, Kari, Neumann, Avidan U., O'Mahony, Liam, Rabenja, Fahafahantsoa Rapelanoro, Renz, Harald, Rhyner, Claudio, Rietschel, Ernst, Ring, Johannes, Roduit, Caroline, Sasaki, Mari, Schenk, Mirjam, Schroeder, Jens, Simon, Dagmar, Simon, Hans-Uwe, Sokolowska, Milena, Staender, Sonja, Steinhoff, Martin, Piccirillo, Doris Straub, Taieb, Alain, Takaoka, Roberto, Tapparo, Martin, Teixeira, Henrique, Thyssen, Jacob Pontoppidan, Traidl, Stephan, Uhlmann, Miriam, van de Veen, Willem, van Hage, Marianne, Virchow, Christian, Wollenberg, Andreas, Yasutaka, Mitamura, Zink, Alexander, and Schmid-Grendelmeier, Peter

Abstract

The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.

Published
2024

17. Eosinophils Play a Surprising Leading Role in Recurrent Urticaria in Horses

Author

Birkmann, Katharina; https://orcid.org/0000-0002-1142-2132, Jebbawi, Fadi; https://orcid.org/0000-0001-6055-6818, Waldern, Nina; https://orcid.org/0000-0001-5971-7442, Hug, Sophie; https://orcid.org/0000-0002-0764-0030, Inversini, Victoria; https://orcid.org/0009-0001-1451-6054, Keller, Giulia, Holm, Anja, Grest, Paula; https://orcid.org/0009-0009-1594-1149, Canonica, Fabia; https://orcid.org/0000-0003-4324-3961, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Fettelschoss-Gabriel, Antonia; https://orcid.org/0000-0002-6189-172X, Birkmann, Katharina; https://orcid.org/0000-0002-1142-2132, Jebbawi, Fadi; https://orcid.org/0000-0001-6055-6818, Waldern, Nina; https://orcid.org/0000-0001-5971-7442, Hug, Sophie; https://orcid.org/0000-0002-0764-0030, Inversini, Victoria; https://orcid.org/0009-0001-1451-6054, Keller, Giulia, Holm, Anja, Grest, Paula; https://orcid.org/0009-0009-1594-1149, Canonica, Fabia; https://orcid.org/0000-0003-4324-3961, Schmid-Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, and Fettelschoss-Gabriel, Antonia; https://orcid.org/0000-0002-6189-172X

Abstract

Urticaria, independent of or associated with allergies, is commonly seen in horses and often shows a high reoccurrence rate. Managing these horses is discouraging, and efficient treatment options are lacking. Due to an incidental finding in a study on horses affected by insect bite hypersensitivity using the eosinophil-targeting eIL-5-CuMV-TT vaccine, we observed the prevention of reoccurring seasonal urticaria in four subsequent years with re-vaccination. In an exploratory case series of horses affected with non-seasonal urticaria, we aimed to investigate the role of eosinophils in urticaria. Skin punch biopsies for histology and qPCR of eosinophil associated genes were performed. Further, two severe, non-seasonal, recurrent urticaria-affected horses were vaccinated using eIL-5-CuMV-TT, and urticaria flare-up was followed up with re-vaccination for several years. Eotaxin-2, eotaxin-3, IL-5, CCR5, and CXCL10 showed high sensitivity and specificity for urticarial lesions, while eosinophils were present in 50% of histological tissue sections. The eIL-5-CuMV-TT vaccine reduced eosinophil counts in blood, cleared clinical signs of urticaria, and even prevented new episodes of urticaria in horses with non-seasonal recurrent urticaria. This indicates that eosinophils play a leading role in urticaria in horses, and targeting eosinophils offers an attractive new treatment option, replacing the use of corticosteroids.

Published
2024

18. Decreased skin colonization with Malassezia spp. and increased skin colonization with Candida spp. in patients with severe atopic dermatitis

Author

Storz, Lukas, Schmid, Bettina, Bosshard, Philipp Peter, Schmid-Grendelmeier, Peter, Brüggen, Marie-Charlotte, Lang, Claudia, Storz, Lukas, Schmid, Bettina, Bosshard, Philipp Peter, Schmid-Grendelmeier, Peter, Brüggen, Marie-Charlotte, and Lang, Claudia

Abstract

Background: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disease in which patients are sensitized towards a plethora of allergens. The hosts fungal microbiota, the mycobiota, that is believed to be altered in patients suffering from AD acts as such an allergen. The correlation context of specific sensitization, changes in mycobiota and its impact on disease severity however remains poorly understood. Objectives: We aim to enhance the understanding of the specific sensitization towards the mycobiota in AD patients in relation to their fungal skin colonization. Methods: Sensitization pattern towards the Malassezia spp. and Candida albicans of 16 AD patients and 14 healthy controls (HC) were analyzed with the newly developed multiplex-assay ALEX2® and the established singleplex-assay ImmunoCAP®. We compared these findings with the fungal skin colonization analyzed by DNA sequencing of the internal transcribed spacer region 1 (ITS1). Results: Sensitization in general and towards Malassezia spp. and C. albicans is increased in AD patients compared to HC with a quantitative difference in severe AD when compared to mild to moderate AD. Further we saw an association between sensitization towards and skin colonization with Candida spp. yet a negative correlation between sensitization towards and skin colonization with Malassezia spp. Conclusion: We conclude that AD in general and severe AD in particular is associated with increased sensitization towards the hosts own mycobiota. There is positive correlation in Candida spp. skin colonization and negative in Malassezia spp. skin colonization when compared to AD, AD severity as well as to specific sensitization patterns.

Published
2024

19. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies

Author

Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Gooderham, Melinda J; https://orcid.org/0000-0001-8926-0113, Hartmann, Karin; https://orcid.org/0000-0002-4595-8226, Konstantinou, George N; https://orcid.org/0000-0003-1371-6764, Fellmann, Marc; https://orcid.org/0000-0003-0064-698X, Koulias, Christopher, Clibborn, Claire; https://orcid.org/0000-0002-2586-891X, Biswas, Pinaki, Brunner, Patrick M; https://orcid.org/0000-0002-3488-3345, Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Gooderham, Melinda J; https://orcid.org/0000-0001-8926-0113, Hartmann, Karin; https://orcid.org/0000-0002-4595-8226, Konstantinou, George N; https://orcid.org/0000-0003-1371-6764, Fellmann, Marc; https://orcid.org/0000-0003-0064-698X, Koulias, Christopher, Clibborn, Claire; https://orcid.org/0000-0002-2586-891X, Biswas, Pinaki, and Brunner, Patrick M; https://orcid.org/0000-0002-3488-3345

Abstract

Background: Abrocitinib efficacy by comorbidity status in patients with moderate‐to‐severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities. Methods: Data were pooled from patients who received abrocitinib 200 mg, 100 mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials. Patients with and without allergic comorbidities (allergic asthma, rhinitis, conjunctivitis, or food allergy) were evaluated for Investigator's Global Assessment (IGA) response (clear [0] or almost clear [1]), ≥75% improvement in the Eczema Area and Severity Index (EASI‐75), ≥4‐point improvement in Peak Pruritus Numerical Rating Scale (PP‐NRS4), and Dermatology Life Quality Index (DLQI) response (<2 with baseline score ≥2). Other outcomes were Patient‐Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD), Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), and treatment‐emergent adverse events (TEAEs). Results: Of 942 patients, 498 (53%) reported at least one allergic comorbidity (asthma only, 33%; conjunctivitis only or rhinitis only or both, 17%; food allergies only, 15%; >1 allergic comorbidity, 34%). Regardless of comorbidity status, from Week 2 to Week 12, higher percentages of patients treated with either abrocitinib dose achieved IGA 0/1, EASI‐75, PP‐NRS4, or DLQI 0/1 versus placebo‐treated patients. Changes from baseline in POEM, SCORAD, and PSAAD were greater with abrocitinib than with placebo in patients with and without allergic comorbidities. Most TEAEs were mild or moderate. Conclusions: Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities.

Published
2024

20. Atopic dermatitis: A global health perspective

Author

Faye, Ousmane, Flohr, Carsten; https://orcid.org/0000-0003-4884-6286, Kabashima, Kenji, Ma, Lin, Paller, Amy S; https://orcid.org/0000-0001-6187-6549, Rapelanoro, Fahafahantsoa Rabenja, Steinhoff, Martin, Su, John C, Takaoka, Roberto, Wollenberg, Andreas; https://orcid.org/0000-0003-0177-8722, Yew, Yik Weng, Postigo, Jose A Ruiz, Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, Taïeb, Alain; https://orcid.org/0000-0002-0928-8608, Faye, Ousmane, Flohr, Carsten; https://orcid.org/0000-0003-4884-6286, Kabashima, Kenji, Ma, Lin, Paller, Amy S; https://orcid.org/0000-0001-6187-6549, Rapelanoro, Fahafahantsoa Rabenja, Steinhoff, Martin, Su, John C, Takaoka, Roberto, Wollenberg, Andreas; https://orcid.org/0000-0003-0177-8722, Yew, Yik Weng, Postigo, Jose A Ruiz, Schmid‐Grendelmeier, Peter; https://orcid.org/0000-0003-3215-3370, and Taïeb, Alain; https://orcid.org/0000-0002-0928-8608

Abstract

The International Society of AD (ISAD) organized a roundtable on global aspects of AD at the WCD 2023 in Singapore. According to the Global Burden of Disease (GBD) consortium, at least 171 million individuals were affected with AD in 2019, corresponding to 2.23% of the world population, with age‐standardized prevalence and incidence rates that were relatively stable from 1990 to 2019. Based on the panel experience, most AD cases are mild‐to‐moderate. Without parallel data on disease prevalence and severity, the GBD data are difficult to interpret in many regions. This gap is particularly important in countries with limited medical infrastructure, but indirect evidence suggests a significant burden of AD in low‐and‐medium resource settings, especially urban areas. The Singapore roundtable was an opportunity to compare experiences in World Bank category 1 (Madagascar and Mali), 3 (Brazil, China) and 4 (Australia, Germany, Qatar, USA, Singapore, Japan) countries. The panel concluded that current AD guidelines are not adapted for low resource settings and a more pragmatic approach, as developed by WHO for skin NTDs, would be advisable for minimal access to moisturizers and topical corticosteroids. The panel also recommended prioritizing prevention studies, regardless of the level of existing resources. For disease long‐term control in World Bank category 3 and most category 4 countries, the main problem is not access to drugs for most mild‐to‐moderate cases, but rather poor compliance due to insufficient time at visits. Collaboration with WHO, patient advocacy groups and industry may promote global change, improve capacity training and fight current inequalities. Finally, optimizing management of AD and its comorbidities needs more action at the primary care level, because reaching specialist care is merely aspirational in most settings. Primary care empowerment with store and forward telemedicine and algorithms based on augmented intelligence is a future goal.

Published
2024

22. A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020

Author

Ansotegui, Ignacio J., Melioli, Giovanni, Canonica, Giorgio Walter, Gómez, R. Maximiliano, Jensen-Jarolim, Erika, Ebisawa, Motohiro, Luengo, Olga, Caraballo, Luis, Passalacqua, Giovanni, Poulsen, Lars K., Savi, Eleonora, Zuberbier, Torsten, Villa, Elisa, Oppenheimer, John, Asero, Riccardo, Bernstein, Jonathan, Bousquet, Jean, Cardona, Victoria, Cox, Lindo, Demoly, Pascal, Ferreira, Fatima, Giavina Bianchi, Pedro, Gonzalez Diaz, Sandra, Jakob, Thilo, Kase Tanno, Luciana, Kleine-Tebbe, Jorg, Levin, Michael, Martin, Bryan, Matricardi, Paolo Maria, Monge Ortega, Olga Patricia, Morais Almeida, Mario, Nunes, Carlos, Ortega Martell, José Antonio, Pawankar, Ruby, Renz, Harald, Rosário Filho, Nelson, Rouadi, Philip, Ruiba, Alessia, Sampson, Hugh, Sánchez Borges, Mario, Scala, Enrico, Schmid-Grendelmeier, Peter, Senna, Gian-Enrico, Sisul, Juan Carlos, Tang, Mimi L.K., Valenta, Rudolf, van Hage, Marianne, Wong, Gary W.K., and Yáñez, Anahí

Published
2020
Full Text
View/download PDF

24. S3‐Leitlinie Atopische Dermatitis: Teil 2 ‐ Systemische Therapie

Author

Werfel, Thomas, primary, Heratizadeh, Annice, additional, Aberer, Werner, additional, Augustin, Matthias, additional, Biedermann, Tilo, additional, Bauer, Andrea, additional, Fölster‐Holst, Regina, additional, Kahle, Julia, additional, Kinberger, Maria, additional, Nemat, Katja, additional, Neustädter, Irena, additional, Peters, Eva, additional, von Kiedrowski, Ralph, additional, Schmid‐Grendelmeier, Peter, additional, Schmitt, Jochen, additional, Schwennesen, Thomas, additional, Simon, Dagmar, additional, Spindler, Thomas, additional, Traidl‐Hoffmann, Claudia, additional, Werner, Ricardo Niklas, additional, Wollenberg, Andreas, additional, Worm, Margitta, additional, and Ott, Hagen, additional

Published
2024
Full Text
View/download PDF

25. S3 Guideline Atopic dermatitis: Part 1 ‐ General aspects, topical and non‐drug therapies, special patient groups

Author

Werfel, Thomas, primary, Heratizadeh, Annice, additional, Aberer, Werner, additional, Augustin, Matthias, additional, Biedermann, Tilo, additional, Bauer, Andrea, additional, Fölster‐Holst, Regina, additional, Kahle, Julia, additional, Kinberger, Maria, additional, Nemat, Katja, additional, Neustädter, Irena, additional, Peters, Eva, additional, von Kiedrowski, Ralph, additional, Schmid‐Grendelmeier, Peter, additional, Schmitt, Jochen, additional, Schwennesen, Thomas, additional, Simon, Dagmar, additional, Spindler, Thomas, additional, Traidl‐Hoffmann, Claudia, additional, Werner, Ricardo Niklas, additional, Wollenberg, Andreas, additional, Worm, Margitta, additional, and Ott, Hagen, additional

Published
2024
Full Text
View/download PDF

26. Atopic dermatitis: A global health perspective

Author

Faye, Ousmane, primary, Flohr, Carsten, additional, Kabashima, Kenji, additional, Ma, Lin, additional, Paller, Amy S., additional, Rapelanoro, Fahafahantsoa Rabenja, additional, Steinhoff, Martin, additional, Su, John C., additional, Takaoka, Roberto, additional, Wollenberg, Andreas, additional, Yew, Yik Weng, additional, Postigo, Jose A. Ruiz, additional, Schmid‐Grendelmeier, Peter, additional, and Taïeb, Alain, additional

Published
2023
Full Text
View/download PDF

30. Kinder mit Atemwegsallergien – Empfehlungen zur Immuntherapie

Author

Eng, Peter Andreas, primary, Bellutti Enders, Felicitas, additional, Borer, Monika, additional, Carrard, Annette, additional, Eigenmann, Philippe, additional, Ferrari, Giovanni, additional, Helbling, Arthur, additional, Hitzler, Michael, additional, Khli, Alice, additional, Kuhn, Alena, additional, Lauener, Roger, additional, Roduit, Caroline, additional, Roth, Michle S., additional, Schmid-Grendelmeier, Peter, additional, Schnider, Caroline, additional, and Fuchs, Oliver, additional

Published
2023
Full Text
View/download PDF

31. A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Author

Zuberbier, Torsten, primary, Abdul Latiff, Amir, additional, Aggelidis, Xenofon, additional, Augustin, Matthias, additional, Balan, Radu‐Gheorghe, additional, Bangert, Christine, additional, Beck, Lisa, additional, Bieber, Thomas, additional, Bernstein, Jonathan A., additional, Bertolin Colilla, Marta, additional, Berardi, Alejandro, additional, Bedbrook, Anna, additional, Bindslev‐Jensen, Carsten, additional, Bousquet, Jean, additional, de Bruin‐Weller, Marjolein, additional, Bruscky, Dayanne, additional, Buyuktiryaki, Betul, additional, Canonica, Giorgio Walter, additional, Castro, Carla, additional, Chanturidze, Natia, additional, Chong‐Neto, Herberto Jose, additional, Chu, Chia‐Yu, additional, Chularojanamontri, Leena, additional, Cork, Michael, additional, Criado, Roberta F. J., additional, Barredo, Laia Curto, additional, Custovic, Adnan, additional, Darsow, Ulf, additional, Emurlai, Arben, additional, de Pablo, Ana, additional, Del Giacco, Stefano, additional, Girolomoni, Giampiero, additional, Deleva Jovanova, Tanja, additional, Deleuran, Mette, additional, Douladiris, Nikolaos, additional, Duarte, Bruno, additional, Dubakiene, Ruta, additional, Eller, Esben, additional, Engel‐Yeger, Batya, additional, Ensina, Luis Felipe, additional, Filho, Nelson Rosario, additional, Flohr, Carsten, additional, Fomina, Daria, additional, Francuzik, Wojciech, additional, Galimberti, Maria Laura, additional, Giménez‐Arnau, Ana M., additional, Godse, Kiran, additional, Mortz, Charlotte Gotthard, additional, Gotua, Maia, additional, Hide, Michihiro, additional, Hoetzenecker, Wolfram, additional, Hunzelmann, Nicolas, additional, Irvine, Alan, additional, Jack, Carolyn, additional, Kanavarou, Ioanna, additional, Katoh, Norito, additional, Kinaciyan, Tamar, additional, Kocatürk, Emek, additional, Kulthanan, Kanokvalai, additional, Lapeere, Hilde, additional, Lau, Susanne, additional, Machado Forti Nastri, Mariana, additional, Makris, Michael, additional, Mansour, Eli, additional, Marsland, Alexander, additional, Morelo Rocha Felix, Mara, additional, Moschione Castro, Ana Paula, additional, Nettis, Eustachio, additional, Nicolas, J. F., additional, Nosbaum, Audrey, additional, Odemyr, Mikaela, additional, Papapostolou, Niki, additional, Parisi, Claudio A. S., additional, Paudel, Sushil, additional, Peter, Jonny, additional, Pokharel, Prakash, additional, Puig, Luis, additional, Quint, Tamara, additional, Ramon, German Dario, additional, Regateiro, Frederico, additional, Ricci, Giampaolo, additional, Rosario, Cristine, additional, Sackesen, Cansin, additional, Schmid‐Grendelmeier, Peter, additional, Serra‐Baldrich, Esther, additional, Siemens, Kristina, additional, Smith, Cathrine, additional, Staubach, Petra, additional, Stevanovic, Katarina, additional, Su‐Kücük, Özlem, additional, Sussman, Gordon, additional, Tavecchio, Simona, additional, Teovska Mitrevska, Natasa, additional, Thaci, Diamant, additional, Toubi, Elias, additional, Traidl‐Hoffmann, Claudia, additional, Treudler, Regina, additional, Vadasz, Zahava, additional, van Hofman, Ingrid, additional, Ventura, Maria Teresa, additional, Wang, Zhao, additional, Werfel, Thomas, additional, Wollenberg, Andreas, additional, Yang, Ariana, additional, Weng Yew, Yik, additional, Zhao, Zuotao, additional, Zwiener, Ricardo, additional, and Worm, Margitta, additional

Published
2023
Full Text
View/download PDF

34. In chronic spontaneous urticaria soluble FcεRI is elevated and linked to atopy and chronic inducible urticaria

Author

Moñino‐Romero, Sherezade, primary, Kolkhir, Pavel, additional, Szépfalusi, Zsolt, additional, Schoepke, Nicole, additional, Metz, Martin, additional, Asero, Riccardo, additional, Ferrer, Marta, additional, Gimenez‐Arnau, Ana, additional, Grattan, Clive E. H., additional, Jakob, Thilo, additional, Konstantinou, George N., additional, Raap, Ulrike, additional, Staubach, Petra, additional, Zhang, Ke, additional, Bindslev‐Jensen, Carsten, additional, Daschner, Alvaro, additional, Kinaciyan, Tamar, additional, Makris, Michael, additional, Marrouche, Nadine, additional, Schmid‐Grendelmeier, Peter, additional, Sussman, Gordon, additional, Toubi, Elias, additional, Maurer, Marcus, additional, and Altrichter, Sabine, additional

Published
2023
Full Text
View/download PDF

38. Obesity and disease severity magnify disturbed microbiome-immune interactions in asthma patients

Author

Michalovich, David, Rodriguez-Perez, Noelia, Smolinska, Sylwia, Pirozynski, Michal, Mayhew, David, Uddin, Sorif, Van Horn, Stephanie, Sokolowska, Milena, Altunbulakli, Can, Eljaszewicz, Andrzej, Pugin, Benoit, Barcik, Weronika, Kurnik-Lucka, Magdalena, Saunders, Ken A., Simpson, Karen D., Schmid-Grendelmeier, Peter, Ferstl, Ruth, Frei, Remo, Sievi, Noriane, Kohler, Malcolm, Gajdanowicz, Pawel, Graversen, Katrine B., Lindholm Bøgh, Katrine, Jutel, Marek, Brown, James R., Akdis, Cezmi A., Hessel, Edith M., and O’Mahony, Liam

Published
2019
Full Text
View/download PDF

40. S3 guideline Atopic dermatitis: Part 2 ‐ Systemic treatment.

Author

Werfel, Thomas, Heratizadeh, Annice, Aberer, Werner, Augustin, Matthias, Biedermann, Tilo, Bauer, Andrea, Fölster‐Holst, Regina, Kahle, Julia, Kinberger, Maria, Nemat, Katja, Neustädter, Irena, Peters, Eva, von Kiedrowski, Ralph, Schmid‐Grendelmeier, Peter, Schmitt, Jochen, Schwennesen, Thomas, Simon, Dagmar, Spindler, Thomas, Traidl‐Hoffmann, Claudia, and Werner, Ricardo Niklas

Abstract

Summary: The present S3 guideline was created based on the European English‐language S3 guideline, with special consideration given to the medical conditions in the German‐speaking region, and with additions from the previous German‐language version, in accordance with the criteria of the AWMF. This second part of the guideline addresses the systemic therapy of atopic dermatitis (AD). It covers topics such as the indication for systemic therapy in children, adolescents, and adult patients with AD. Furthermore, it addresses all medications approved for AD, such as the biologics dupilumab and tralokinumab, the Janus kinase inhibitors abrocitinib, baricitinib, and upadacitinib, as well as conventional immunosuppressive therapies with systemic glucocorticosteroids and ciclosporin. Additionally, it discusses systemic off‐label therapies. The first part of the guideline, published separately, includes the definition and diagnostic aspects of AD, describes topical therapy, non‐drug therapy approaches, and addresses aspects related to special patient groups. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Efficacy and safety of abrocitinib in patients with moderate‐to‐severe atopic dermatitis and comorbid allergies.

Author

Schmid‐Grendelmeier, Peter, Gooderham, Melinda J., Hartmann, Karin, Konstantinou, George N., Fellmann, Marc, Koulias, Christopher, Clibborn, Claire, Biswas, Pinaki, and Brunner, Patrick M.

Subjects
*ATOPIC dermatitis, *PATIENT safety, *ALLERGIES, *FOOD allergy, *COMORBIDITY
Abstract

Background: Abrocitinib efficacy by comorbidity status in patients with moderate‐to‐severe atopic dermatitis (AD) has not been previously assessed. This post hoc analysis evaluated the efficacy and safety of abrocitinib in patients with AD and allergic comorbidities. Methods: Data were pooled from patients who received abrocitinib 200 mg, 100 mg, or placebo in phase 2b (NCT02780167) and phase 3 (NCT03349060, NCT03575871) monotherapy trials. Patients with and without allergic comorbidities (allergic asthma, rhinitis, conjunctivitis, or food allergy) were evaluated for Investigator's Global Assessment (IGA) response (clear [0] or almost clear [1]), ≥75% improvement in the Eczema Area and Severity Index (EASI‐75), ≥4‐point improvement in Peak Pruritus Numerical Rating Scale (PP‐NRS4), and Dermatology Life Quality Index (DLQI) response (<2 with baseline score ≥2). Other outcomes were Patient‐Oriented Eczema Measure (POEM), SCORing Atopic Dermatitis (SCORAD), Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD), and treatment‐emergent adverse events (TEAEs). Results: Of 942 patients, 498 (53%) reported at least one allergic comorbidity (asthma only, 33%; conjunctivitis only or rhinitis only or both, 17%; food allergies only, 15%; >1 allergic comorbidity, 34%). Regardless of comorbidity status, from Week 2 to Week 12, higher percentages of patients treated with either abrocitinib dose achieved IGA 0/1, EASI‐75, PP‐NRS4, or DLQI 0/1 versus placebo‐treated patients. Changes from baseline in POEM, SCORAD, and PSAAD were greater with abrocitinib than with placebo in patients with and without allergic comorbidities. Most TEAEs were mild or moderate. Conclusions: Efficacy and safety data support abrocitinib use to manage AD in patients with or without allergic comorbidities. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Electrical impedance spectroscopy detects skin barrier dysfunction in childhood atopic dermatitis.

Author

Sasaki, Mari, Sundberg, Mathilda, Frei, Remo, Ferstl, Ruth, Heye, Kristina N., Willems, Erik P., Akdis, Cezmi A., Lauener, Roger, Bieber, Thomas, Schmid‐Grendelmeier, Peter, Traidl‐Hoffmann, Claudia, Brüggen, Marie‐Charlotte, Rhyner, Claudio, and Roduit, Caroline

Subjects
ELECTRIC impedance, ATOPIC dermatitis, IMPEDANCE spectroscopy, MACHINE learning, CHILD care
Abstract

Background: Skin barrier dysfunction is associated with the development of atopic dermatitis (AD), however methods to assess skin barrier function are limited. We investigated the use of electrical impedance spectroscopy (EIS) to detect skin barrier dysfunction in children with AD of the CARE (Childhood AlleRgy, nutrition, and Environment) cohort. Methods: EIS measurements taken at multiple time points from 4 months to 3‐year‐old children, who developed AD (n = 66) and those who did not (n = 49) were investigated. Using only the EIS measurement and the AD status, we developed a machine learning algorithm that produces a score (EIS/AD score) which reflects the probability that a given measurement is from a child with active AD. We investigated the diagnostic ability of this score and its association with clinical characteristics and age. Results: Based on the EIS/AD score, the EIS algorithm was able to clearly discriminate between healthy skin and clinically unaffected skin of children with active AD (area under the curve 0.92, 95% CI 0.85–0.99). It was also able to detect a difference between healthy skin and AD skin when the child did not have active AD. There was no clear association between the EIS/AD score and the severity of AD or sensitisation to the tested allergens. The performance of the algorithm was not affected by age. Conclusions: This study shows that EIS can detect skin barrier dysfunction and differentiate skin of children with AD from healthy skin and suggests that EIS may have the ability to predict future AD development. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. S3‐Leitlinie Atopische Dermatitis: Teil 1‐ Allgemeine Aspekte, topische und nichtmedikamentöse Therapien, besondere Patientengruppen: S3 guideline Atopic dermatitis: Part 1‐ General aspects, topical and non‐drug therapies, special patient groups

Author

Werfel, Thomas, Heratizadeh, Annice, Aberer, Werner, Augustin, Matthias, Biedermann, Tilo, Bauer, Andrea, Fölster‐Holst, Regina, Kahle, Julia, Kinberger, Maria, Nemat, Katja, Neustädter, Irena, Peters, Eva, von Kiedrowski, Ralph, Schmid‐Grendelmeier, Peter, Schmitt, Jochen, Schwennesen, Thomas, Simon, Dagmar, Spindler, Thomas, Traidl‐Hoffmann, Claudia, and Werner, Ricardo Niklas

Abstract

Copyright of Journal der Deutschen Dermatologischen Gesellschaft is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Published
2024
Full Text
View/download PDF

44. Immunoglobulin E autoantibodies in atopic dermatitis associate with Type‐2 comorbidities and the atopic march.

Author

Kortekaas Krohn, Inge, Badloe, Fariza Mishaal Saiema, Herrmann, Nadine, Maintz, Laura, De Vriese, Shauni, Ring, Johannes, Schmid‐Grendelmeier, Peter, Traidl‐Hoffmann, Claudia, Akdis, Cezmi, Lauener, Roger, Brüggen, Marie‐Charlotte, Rhyner, Claudio, Bersuch, Eugen, Dreher, Anita, Hammel, Gertrud, Luschkova, Daria, Lang, Claudia, Reiger, Matthias, Bieber, Thomas, and Gutermuth, Jan

Subjects
IMMUNOGLOBULIN E, AUTOANTIBODIES, ATOPIC dermatitis, ALLERGIC rhinitis, FOOD allergy
Abstract

Background: Autoreactive immunoglobulin E (IgE) antibodies to self‐peptides within the epidermis have been identified in patients with atopic dermatitis (AD). Prevalence, concomitant diseases, patient characteristics, and risk factors of IgE autoantibody development remain elusive. We aimed to determine IgE autoantibodies in serum samples (n = 672) from well‐characterized patients with AD and controls (1.2–88.9 years). Methods: Atopic dermatitis patients were sub‐grouped in AD with comorbid Type‐2 diseases ("AD + Type 2"; asthma, allergic rhinitis, food allergy, n = 431) or "solely AD" (n = 115). Also, subjects without AD but with Type‐2 diseases ("atopic controls," n = 52) and non‐atopic "healthy controls" (n = 74) were included. Total proteins from primary human keratinocytes were used for the immunoassay to detect IgE autoantibodies. Values were compared to already known positive and negative serum samples. Results: Immunoglobulin E autoantibodies were found in 15.0% (82/546) of all analyzed AD‐patients. "AD + Type 2" showed a higher prevalence (16.4%) than "solely AD" (9.6%). "Atopic controls" (9.6%) were comparable with "solely AD" patients, while 2.7% of healthy controls showed IgE autoantibodies. Of those with high levels of IgE autoantibodies, 15 out of 16 were patients with "AD + Type 2". AD patients with IgE autoantibodies were younger than those without. Patients with IgE autoreactivity also displayed higher total serum IgE levels. Factors that affected IgE autoantibody development were as follows: birth between January and June, cesarean‐section and diversity of domestic pets. Conclusions: Immunoglobulin E autoantibodies in AD seem to associate with the presence of atopic comorbidities and environmental factors. The potential value of IgE autoantibodies as a predictive biomarker for the course of AD, including the atopic march, needs further exploration. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Autorenverzeichnis

Author

Ackermann-Burkhart, Ulrike, primary, Backmund, Markus, additional, Bausewein, Claudia, additional, Beier, Klaus M., additional, Bender, Wolfram, additional, Beutel, Manfred E., additional, Boetsch, Thomas, additional, Bolle, Ralf, additional, Boll-Klatt, Annegret, additional, Breindl-Sarbia, Karolina, additional, Breuer-Umlauf, Monika, additional, Bronisch, Thomas, additional, Buchheim, Anna, additional, Burgemeister, Dorothee, additional, Connert, Senta, additional, Danner-Weinberger, Alexandra, additional, Eberhard-Kaechele, Marianne, additional, Eyer, Florian, additional, Falk, Gudrun, additional, Frank, Reiner, additional, Fritsche, Jürgen, additional, Fröhlich-Gildhoff, Klaus, additional, Fuchs, Thomas, additional, Führer, Monika, additional, Gerstberger, Gerhard, additional, Gräff, Christine, additional, Gromes, Barbara, additional, Günter, Michael, additional, Hamberger, Christian, additional, Henningsen, Christina, additional, Henningsen, Peter, additional, Hess, Thomas, additional, Hesse, Gerhard, additional, Heuft, Gereon, additional, Heußner, Pia, additional, Hölz-Lindau, Begga, additional, Holzmann, Tanja, additional, Jallerat, Diana, additional, Junker, Johannes, additional, Kächele, Horst, additional, Kapaun, Petra, additional, Kast, Verena, additional, Kiechle, Marion, additional, Kirchlechner, Helmut, additional, Korte, Alexander, additional, Künstler, Constanze, additional, Kux, Regine, additional, Astrid Lenné, M.A., additional, Machleidt, Wielant, additional, Martius, Philipp, additional, Mechler-Schönach, Christine, additional, Menzel, Susanne, additional, Möhrenschlager, Matthias, additional, Möller-Leimkühler, Anne Maria, additional, Mußgnug-Kempmann-Hirsch, Ursula, additional, Nowak, Dennis, additional, Pirklbauer, Susanne, additional, Rauchfleisch, Udo, additional, Rentrop, Michael, additional, Riedel, Ingrid, additional, Ring, Johannes, additional, Rümmelein, Nina, additional, Sack, Martin, additional, Schattmayer-Bolle, Klara, additional, Schleuning, Gabriele, additional, Schmid-Grendelmeier, Peter, additional, Schneider, Gudrun, additional, Schottenloher, Gertraud, additional, Sellschopp, Almuth, additional, Starke, Claudia, additional, Staroszynski, Thomas, additional, Steger, Florian, additional, Strauß, Bernhard, additional, Thomas-Roper, Angelika, additional, Timmermann, Tonius, additional, Titze, Doris, additional, Trautmann-Voigt, Sabine, additional, Utikal, Anne, additional, von Gontard, Alexander, additional, von Moreau, Dorothee, additional, von Spreti, Flora, additional, von Wietersheim, Jörn, additional, and Wiendl, Renate, additional

Published
2019
Full Text
View/download PDF

48. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood

Author

Maintz, Laura, primary, Schmitz, Marie‐Therese, additional, Herrmann, Nadine, additional, Müller, Svenja, additional, Havenith, Regina, additional, Brauer, Juliette, additional, Rhyner, Claudio, additional, Dreher, Anita, additional, Bersuch, Eugen, additional, Fehr, Danielle, additional, Hammel, Gertrud, additional, Reiger, Matthias, additional, Luschkova, Daria, additional, Neumann, Avidan, additional, Lang, Claudia C. V., additional, Renner, Ellen D., additional, Schmid‐Grendelmeier, Peter, additional, Traidl‐Hoffmann, Claudia, additional, Akdis, Cezmi A., additional, Lauener, Roger, additional, Brüggen, Marie‐Charlotte, additional, Schmid, Matthias, additional, and Bieber, Thomas, additional

Published
2023
Full Text
View/download PDF

50. EAACI Molecular Allergology User's Guide 2.0

Author

Dramburg, Stephanie, primary, Hilger, Christiane, additional, Santos, Alexandra F., additional, de las Vecillas, Leticia, additional, Aalberse, Rob C., additional, Acevedo, Nathalie, additional, Aglas, Lorenz, additional, Altmann, Friedrich, additional, Arruda, Karla L., additional, Asero, Riccardo, additional, Ballmer‐Weber, Barbara, additional, Barber, Domingo, additional, Beyer, Kirsten, additional, Biedermann, Tilo, additional, Bilo, Maria Beatrice, additional, Blank, Simon, additional, Bosshard, Philipp P., additional, Breiteneder, Heimo, additional, Brough, Helen A., additional, Bublin, Merima, additional, Campbell, Dianne, additional, Caraballo, Luis, additional, Caubet, Jean Christoph, additional, Celi, Giorgio, additional, Chapman, Martin D., additional, Chruszcz, Maksymilian, additional, Custovic, Adnan, additional, Czolk, Rebecca, additional, Davies, Janet, additional, Douladiris, Nikolaos, additional, Eberlein, Bernadette, additional, Ebisawa, Motohiro, additional, Ehlers, Anna, additional, Eigenmann, Philippe, additional, Gadermaier, Gabriele, additional, Giovannini, Mattia, additional, Gomez, Francisca, additional, Grohman, Rebecca, additional, Guillet, Carole, additional, Hafner, Christine, additional, Hamilton, Robert G., additional, Hauser, Michael, additional, Hawranek, Thomas, additional, Hoffmann, Hans Jürgen, additional, Holzhauser, Thomas, additional, Iizuka, Tomona, additional, Jacquet, Alain, additional, Jakob, Thilo, additional, Janssen‐Weets, Bente, additional, Jappe, Uta, additional, Jutel, Marek, additional, Kalic, Tanja, additional, Kamath, Sandip, additional, Kespohl, Sabine, additional, Kleine‐Tebbe, Jörg, additional, Knol, Edward, additional, Knulst, André, additional, Konradsen, Jon R., additional, Korošec, Peter, additional, Kuehn, Annette, additional, Lack, Gideon, additional, Le, Thuy‐My, additional, Lopata, Andreas, additional, Luengo, Olga, additional, Mäkelä, Mika, additional, Marra, Alessandro Maria, additional, Mills, Clare, additional, Morisset, Martine, additional, Muraro, Antonella, additional, Nowak‐Wegrzyn, Anna, additional, Nugraha, Roni, additional, Ollert, Markus, additional, Palosuo, Kati, additional, Pastorello, Elide Anna, additional, Patil, Sarita Ulhas, additional, Platts‐Mills, Thomas, additional, Pomés, Anna, additional, Poncet, Pascal, additional, Potapova, Ekaterina, additional, Poulsen, Lars K., additional, Radauer, Christian, additional, Radulovic, Suzana, additional, Raulf, Monika, additional, Rougé, Pierre, additional, Sastre, Joaquin, additional, Sato, Sakura, additional, Scala, Enrico, additional, Schmid, Johannes M., additional, Schmid‐Grendelmeier, Peter, additional, Schrama, Denise, additional, Sénéchal, Hélène, additional, Traidl‐Hoffmann, Claudia, additional, Valverde‐Monge, Marcela, additional, van Hage, Marianne, additional, van Ree, Ronald, additional, Verhoeckx, Kitty, additional, Vieths, Stefan, additional, Wickman, Magnus, additional, Zakzuk, Josefina, additional, Matricardi, Paolo M., additional, and Hoffmann‐Sommergruber, Karin, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results